The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism
Citation
Khalpey, Zain, Matthew A. Nehs, Andrew W. ElBardissi, Marcus Semel, and Stefan G. Tullius. 2009. “The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism.” NDT Plus 3 (1): 68-70. doi:10.1093/ndtplus/sfp120. http://dx.doi.org/10.1093/ndtplus/sfp120.Abstract
A 43-year-old African American with end-stage renal disease (ESRD) associated with membranous nephropathy and a previously failed renal transplant had received cinacalcet to treat his secondary hyperparathyroidism. Serum calcium and phosphorus levels remained within normal limits, and serum parathyroid levels had dropped significantly following treatment initiation. However, within 7 months, the patient experienced extensive necrotic bilateral medial thigh ulcers. These were biopsied and found to be a result of calciphylaxis. The patient ultimately required an urgent subtotal parathyroidectomy and recovered well with completely healed ulcers.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421548/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:16120866
Collections
- HMS Scholarly Articles [17922]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)